VOLITIONRX LTD
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
VNRX$0.18-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Deficit
Consolidated Statement of Stockholders’ Deficit
For the Years Ended December 31, 2025 and 2024
| Common Stock · Additional Paid in · Accumulated Other Comprehensive · Accumulated · Non Controlling | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Interest | Total | |
| # | $ | $ | $ | $ | $ | $ | |
| Balance, December 31, 2023 | 81,898,321 | 81,898 | 194,448,414 | 243,940 | (202,576,507) | (909,967) | (8,712,222) |
| Common stock issued for settlement of RSUs | 730,395 | 731 | (731) | - | - | - | - |
| Common stock issued in lieu of license fee | 129,132 | 129 | 125,258 | - | - | - | 125,387 |
| Common stock issued for cash, net of issuance costs and allocation to warrant liability | 13,339,637 | 13,340 | 8,453,449 | - | - | - | 8,466,789 |
| Tax withholdings paid related to stock-based compensation | - | - | (139,939) | - | - | - | (139,939) |
| Stock-based compensation | - | - | 1,268,543 | - | - | - | 1,268,543 |
| Foreign currency translation | - | - | - | 141,691 | - | - | 141,691 |
| Net loss | - | - | - | - | (26,967,836) | (290,149) | (27,257,985) |
| Balance, December 31, 2024 | 96,097,485 | 96,098 | 204,154,994 | 385,631 | (229,544,343) | (1,200,116) | (26,107,736) |
| Common stock issued for settlement of RSUs | 2,091,000 | 2,091 | (2,091) | - | - | - | - |
| Common stock issued for cash, net of issuance costs | 24,034,011 | 24,034 | 11,142,819 | - | - | - | 11,166,853 |
| Issuance of warrants in connection with convertible note offering | - | - | 1,998,869 | - | - | - | 1,998,869 |
| Common stock issued for cash upon exercise of warrants | 3,557,273 | 3,557 | - | - | - | - | 3,557 |
| Tax withholdings paid related to stock-based compensation | - | - | (210,034) | - | - | - | (210,034) |
| Stock-based compensation | - | - | 1,636,138 | - | - | - | 1,636,138 |
| Stock-based compensation in relation to modification of options | - | - | 103,573 | - | - | - | 103,573 |
| Foreign currency translation | - | - | - | (680,702) | - | - | (680,702) |
| Net loss | - | - | - | - | (23,357,027) | (146,302) | (23,503,329) |
| Balance, December 31, 2025 | 125,779,769 | 125,780 | 218,824,268 | (295,071) | (252,901,370) | (1,346,418) | (35,592,811) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.